Real-World Evidence Supports Dupilumab in Pediatric and Adult head and neck atopic dermatitis Patients: Study

Atopic dermatitis (AD) is a chronic inflammatory skin disease driven by type 2 inflammation, with prevalence rates of 15–25% in children and 3–7% in adults worldwide. At present, the treatment of Atopic dermatitis includes basic moisturization, topical agents, phototherapy, systemic medications, and targeted therapies. For mild Atopic dermatitis, moisturizers, topical corticosteroids, or calcineurin inhibitors are commonly used. For moderate-to-severe cases, phototherapy and conventional systemic immunosuppressants are utilized. In recent years, targeted therapies, such as dupilumab and Janus Kinase (JAK) inhibitors, have revolutionized the management of moderate-to-severe Atopic dermatitis, demonstrating significant efficacy and improved safety profiles compared with traditional immunosuppressant. Head and neck atopic dermatitis (HNAD) is a clinically common subtype of Atopic dermatitis. While dupilumab is widely used in Atopic dermatitis treatment, its efficacy in Head and neck atopic dermatitis is debatable. This study aimed to evaluate the real-world efficacy and safety of dupilumab in Head and neck atopic dermatitis. A retrospective study included 29 individuals with Head and neck atopic dermatitis (17 adults and 12 pediatric patients) who were treated with dupilumab. Primary variables, including the Eczema Area and Severity Index (EASI), the Dermatology Life Quality Index (DLQI), Investigator’s Global Assessment (IGA), Patient-Oriented Eczema Measure (POEM), Visual Analog Scale for Itch (VAS-Itch), and Visual Analog Scale for Sleep Quality (VAS-SQ), were evaluated at baseline, week 4, week 8, and week 16. Data on adverse events (AEs) were routinely collected.